NasdaqCM:OCGNBiotechs
Is Ocugen (OCGN) Quietly Reframing Its Risk Profile Around Rare Disease Gene Therapies?
Ocugen, Inc. recently presented at the Oppenheimer Movers in Rare Disease Summit in New York City on 11 December 2025, with Co-Founder, CEO and Chairman Shankar Musunuri highlighting the company’s rare disease focus.
This appearance gives Ocugen a platform to spotlight its gene and cell therapy pipeline to an audience focused on rare diseases, potentially shaping expectations around its development path and partnering opportunities.
We’ll now examine how this rare disease summit appearance...